FI961000A - Embodiments of myelin oligodendrocyte glycoprotein and peptide portions thereof in autoimmune disease method - Google Patents

Embodiments of myelin oligodendrocyte glycoprotein and peptide portions thereof in autoimmune disease method Download PDF

Info

Publication number
FI961000A
FI961000A FI961000A FI961000A FI961000A FI 961000 A FI961000 A FI 961000A FI 961000 A FI961000 A FI 961000A FI 961000 A FI961000 A FI 961000A FI 961000 A FI961000 A FI 961000A
Authority
FI
Finland
Prior art keywords
autoimmune disease
myelin oligodendrocyte
oligodendrocyte glycoprotein
peptide portions
disease method
Prior art date
Application number
FI961000A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI961000A0 (en
Inventor
Brigitte Devaux
Jonathan B Rothbard
Dawn Smilek
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of FI961000A0 publication Critical patent/FI961000A0/en
Publication of FI961000A publication Critical patent/FI961000A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
FI961000A 1993-09-03 1996-03-04 Embodiments of myelin oligodendrocyte glycoprotein and peptide portions thereof in autoimmune disease method FI961000A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11682493A 1993-09-03 1993-09-03
PCT/US1994/010257 WO1995006727A2 (en) 1993-09-03 1994-09-01 Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease

Publications (2)

Publication Number Publication Date
FI961000A0 FI961000A0 (en) 1996-03-04
FI961000A true FI961000A (en) 1996-03-04

Family

ID=22369451

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961000A FI961000A (en) 1993-09-03 1996-03-04 Embodiments of myelin oligodendrocyte glycoprotein and peptide portions thereof in autoimmune disease method

Country Status (9)

Country Link
EP (1) EP0716696A1 (en)
JP (1) JPH09502346A (en)
KR (1) KR960705038A (en)
AU (1) AU7725894A (en)
CA (1) CA2170901A1 (en)
FI (1) FI961000A (en)
NO (1) NO960858D0 (en)
NZ (1) NZ273813A (en)
WO (1) WO1995006727A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4278296A (en) * 1994-10-25 1996-05-15 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
DE69637391T2 (en) * 1995-05-02 2008-08-14 Alexion Pharmaceuticals, Inc., Cheshire MODIFIED MYELIN PROTEIN MOLECULES
CA2250361A1 (en) * 1996-03-28 1997-10-02 Barbara Wallner Myelin oligodendrocyte glycoprotein peptides and uses thereof
WO1998033912A1 (en) * 1997-01-30 1998-08-06 Human Genome Sciences, Inc. MYELIN OLIGODENDROCYTE GLYCOPROTEIN-LIKE PROTEIN (MOGp) AND METHODS OF USE
SE9703287D0 (en) * 1997-09-11 1997-09-11 Astra Ab Peptides
ZA9810133B (en) * 1997-11-07 1999-05-17 Biogen Inc BMOG a novel protein member of the myelin-oligodendrocyte glycoprotein family and its use for ummonomodulatory purposes
EP1115425B1 (en) * 1998-08-26 2007-03-21 The Regents of the University of California Autoantibody inhibitors
CN1301756A (en) * 1999-12-29 2001-07-04 复旦大学 New polypeptide-myelin PO protein 14 and polynucleotide coding such polypeptide
CN1352087A (en) * 2000-11-02 2002-06-05 上海博德基因开发有限公司 New polypeptide-human glycoprotein 42 and polynucleotide for encoding such polypeptide
WO2007008933A2 (en) * 2005-07-11 2007-01-18 Carantech Biosciences, Inc. Compositions and methods comprising complex alternative splice variants of myelin/oligodendrocyte genes (mogs) and antibodies directed thereto
CN101897964B (en) * 2009-04-27 2013-04-10 中国农业大学 Medicament for preventing autoimmune disease
WO2013020914A1 (en) * 2011-08-10 2013-02-14 Celares Gmbh Peg-conjugated peptides
GB201300684D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
AU2015249328B2 (en) * 2014-04-24 2019-01-17 University Of Florida Research Foundation, Inc. AAV-based gene therapy for multiple sclerosis
CN110536901B (en) 2016-12-26 2024-06-18 协和麒麟株式会社 Antibodies that bind myelin oligodendrocyte glycoprotein
US11334352B1 (en) 2020-12-29 2022-05-17 Kpn Innovations, Llc. Systems and methods for generating an immune protocol for identifying and reversing immune disease

Also Published As

Publication number Publication date
NO960858L (en) 1996-03-01
FI961000A0 (en) 1996-03-04
JPH09502346A (en) 1997-03-11
NZ273813A (en) 1998-05-27
AU7725894A (en) 1995-03-22
WO1995006727A2 (en) 1995-03-09
CA2170901A1 (en) 1995-03-09
KR960705038A (en) 1996-10-09
NO960858D0 (en) 1996-03-01
WO1995006727A3 (en) 1995-04-13
EP0716696A1 (en) 1996-06-19

Similar Documents

Publication Publication Date Title
FI961000A (en) Embodiments of myelin oligodendrocyte glycoprotein and peptide portions thereof in autoimmune disease method
DE69535031D1 (en) Selective acylation of epsilon-amino groups in insulin
FI944881A0 (en) Procedure and arrangements for the dissemination of information
FI954559A0 (en) YY peptide analogues and their uses
KR950702113A (en) AMINIMIDE-CONTAINING MOLECULES AND MATERIALS AS MOLECULAR RECOGNITION AGENTS
FI952656A0 (en) Foerfarande and anordning vid pulsmaetning av en person
EP0967992A4 (en) Peptide vaccine to prevent development of several herpes virus infections and/or atherosclerotic plaque
BR9707613A (en) Mixtures free of polypholic derivatives process of preparing mixtures i and ii medications and use of mixtures
EP0729300A4 (en) Novel fas protein and methods of use thereof
ITTO910205A0 (en) PRODUCTION OF HIGH TENACITY AND LOW SHRINKAGE POLYESTER FIBER.
BR9708505A (en) Injection process or model and co-injection process
IT1227268B (en) IMPROVEMENT IN BATHTUBS AND PROCEDURE FOR THEIR MANUFACTURE
KR940027054U (en) Combined structure of motor set and motor
ITMI931334A0 (en) COMPATIBLE POLYMER MIXTURES OF POLYCARBONATE AND POLYAMIDES
AU7731398A (en) Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
KR970011924U (en) Car key and its storage case
BR9202682A (en) POLYESTER RECLINING AND BENEFIT PROCESS
BR9500143A (en) Process of thermogenesis and oxygenation
BR9403296A (en) Freeze-drying process of lemon juice and instant caipirinha kit
KR970023239U (en) Combined structure of fender liner and fender
NO932538D0 (en) REGISTRATION OF SUBSTANCES IN VASKE
KR970004602U (en) Tire Extruded Shrinkage and Conveyer
FR2735973B1 (en) INFLATABLE ANTI-EQUINE AND ANTI-DECARRE BOOT
KR950015229U (en) Car audio with preset scan and scan at power-on
KR950017245U (en) Assembly structure of main core and split core of injection mold